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Abstract Coexistence of hypertension, diabetes mellitus and
chronic kidney disease synergistically aggravates the risk of
cardiovascular and renal morbidity and mortality. These high-
risk, multi-morbid patient populations benefit less from cur-
rently available anti-hypertensive treatment. Simultaneous an-
giotensin II type 1 receptor blockade and neprilysin inhibition
(‘ARNI’) with valsartan/sacubitril (LCZ696) might potentiate
the beneficial effects of renin-angiotensin-aldosterone inhibi-
tion by reinforcing its endogenous counterbalance, the natri-
uretic peptide system. This review discusses effects obtained
with this approach in animals and humans. In animal models
of hypertension, either alone or in combination with myocar-
dial infarction or diabetes, ARNI consistently reduced heart
weight and cardiac fibrosis in a blood pressure-independent
manner. Additionally, LCZ696 treatment reduced proteinuria,
focal segmental glomerulosclerosis and retinopathy, thus si-
multaneously demonstrating favourable effects on microvas-
cular complications. These results were confirmed in patient
populations. Besides blood pressure reductions in hypertensive
patients and greatly improved (cardiovascular) mortality in heart
failure patients, ventricular wall stress and albuminuria were re-
duced particularly in diabetic patients. The exact underlying
mechanism remains unknown, but may involve improved renal
haemodynamics and reduced glomerulosclerosis, e.g. related to a
rise in natriuretic peptide levels. However, the assays of these
peptides are hampered by methodological artefacts. Moreover,
since sacubitrilat is largely renally cleared, drug accumulation
may occur in patients with impaired renal function and thus
hypotension is a potential side effect in patients with chronic
kidney disease. Further caution is warranted since neprilysin also
degrades endothelin-1 and amyloid beta in animal models.
Accumulation of the latter may increase the risk of Alzheimer’s
disease.
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Introduction
Cardiovascular diseases cause nearly one third of all deaths
worldwide [1], and 50% of these deaths are thought to be
directly attributable to hypertension [2]. High blood pressure
is an important risk factor in the development of myocardial
infarction, hypertensive heart disease, heart failure and stroke.
Additionally, hypertension may cause chronic kidney disease
(CKD) and end-stage renal disease (ESRD). Patients with
CKD are more likely to die from cardiovascular disease than
to develop renal failure [3]. They are regarded as a high-risk
population within the general hypertensive population.
Another high-risk population comprises hypertensive patients
with diabetes mellitus. Prevalence of hypertension among di-
abetic patients is reported in most studies to be greater than
60% and in many studies to be even higher than 75% [4].
Coexistence of hypertension and diabetes synergistically ag-
gravates the risk of developing macro- and microvascular
complications [5]. These dismal outcomes emphasize the need
for targeted therapy of these vulnerable multi-morbid patient
populations.
This article is part of the Topical Collection on Hypertension and the
Kidney
* A. H. Jan Danser
a.danser@erasmusmc.nl
1 Division of Pharmacology and Vascular Medicine Department of
Internal Medicine, Erasmus MC, Rotterdam, The Netherlands
2 Division of Nephrology and Transplantation, Department of Internal
Medicine, Erasmus MC, Rotterdam, The Netherlands
Curr Hypertens Rep (2016) 18: 86
DOI 10.1007/s11906-016-0694-x
Treatment of high blood pressure greatly reduces the risk
for all-cause mortality, coronary heart disease, heart failure
and stroke. Development of renal failure, however, is not
prevented by blood pressure lowering, and high-risk popula-
tions benefit less from this approach. Indeed, proportional risk
reductions for major cardiovascular events are lower or absent
in patients with concurrent diabetes or CKD [6]. However,
treatment effects vary between different classes of anti-
hypertensive drugs. Pharmacological inhibition of the renin-
angiotensin-aldosterone system (RAAS) reduces albuminuria
and slows the progression of diabetic nephropathy [7].
Unfortunately, effects on cardiovascular events and all-cause
mortality remain limited. Initially, it was believed that this was
due to incomplete RAAS blockade and RAAS escape phe-
nomena. Although the combination of angiotensin-converting
enzyme inhibition (ACEi) and angiotensin receptor blockade
(ARB) appears to prevent the development of ESRD more
effectively according to one meta-analysis [7], dual therapy
is not recommended [8]. The reason is that near complete
RAAS suppression does not reduce cardiovascular or all-
cause mortality. Yet, it does increase the risk of adverse events,
including hypotension, hyperkalaemia and acute kidney inju-
ry (AKI) [9]. This most likely relates to the fact that angioten-
sin II (Ang II) is essential to preserve renal function and glo-
merular filtration. The kidneys will do everything possible to
keep the latter in the normal range, including massive upreg-
ulation of renin during RAAS blockade [10]. This mechanism
is referred to as the ‘nephrocentric’ reaction to RAAS block-
ade in patients with heart failure [11]. In exceptional cases,
particularly with drugs that accumulate in the kidney (such as
renin inhibitors [12]), the nephrocentric reaction may even
lead to extrarenal RAAS activation. The 8th Joint National
Committee currently recommends ACEi or ARB monothera-
py as first-line treatment for patients with CKD [8]. Clearly,
rather than blocking the RAAS with two or more drugs, there
is a need for interference with alternative systems. This review
aims to critically evaluate the potential for cardiovascular con-
trol of a new anti-hypertensive treatment strategy, the combi-
nation of ARB and neprilysin inhibition: ARNI.
Mechanism of Action
Neprilysin, or neutral endopeptidase (NEP), is a trans-
membrane zinc-dependent metalloprotease with a mo-
lecular weight of approximately 85 kDa. Although
expressed in many epithelial tissues, its levels are par-
ticularly high at the luminal side of the renal proximal
tubule [13, 14]. NEP cleaves peptides and thereby in-
activates peptide hormones such as glucagon, bradyki-
nin, angiotensin, endothelin-1, substance P, oxytocin,
neurotensin, adrenomedullin and natriuretic peptides.
Among these are both vasodilators (e.g. bradykinin,
natriuretic peptides) and vasoconstrictors (e.g. angio-
tensin, endothelin-1). Therefore, the effect of NEP in-
hibition is ambiguous and depends on the relative
dominance of the various substrates of NEP (Fig. 1).
Consequently, NEP inhibition can even raise blood
pressure, as shown in healthy men [15]. It was postu-
lated that the combination of a NEP inhibitor with an
ARB would hold the beneficial effects of increasing
natriuretic peptides and simultaneously block the harm-
ful effects of (the NEP inhibitor-induced increase in)
Ang II. ARBs prevent the binding of Ang II to the
Ang II type 1 (AT1) receptor, thereby inhibiting Ang
II-induced vasoconstriction, aldosterone release, stimu-
lation of the sympathetic nervous system and vascular
as well as cardiac remodeling [16]. Natriuretic peptides
counter the RAAS not only by inducing natriuresis,
diuresis and vasodilation but also by inhibiting renin
secretion, via their second messenger cyclic guanosine
3′5′monophosphate (cGMP) [17]. Therefore, reinforce-
ment of the natriuretic peptide system on top of RAAS
blockade might have a synergistic effect on blood pres-
sure and cardiac remodeling. LCZ696 (sacubitril/
valsartan, brand name Entresto) is the first-in-class
ARNI. It is a single molecule in which the ARB
valsartan and the NEP inhibitor prodrug sacubitril
(AHU377) are combined, in a molar ratio of 1:1 [18].
Sacubitril is almost completely metabolized into its ac-
tive form LBQ657 (also known as sacubitrilat) via es-
ter hydrolysis, rapidly after ingestion [19]. In humans,
sacubitril has a half life of 1.4 h, LBQ657 has a half
life of 11.5 h and valsartan has a half life of 9.9 h.
LBQ657 is excreted through urine, and the exposure to
LBQ657 increases with decreasing renal function [20].
A decrease in renal function does not affect the phar-
macokinetics of valsartan, since it is primarily excreted
via the biliary route [21].
Animal Studies
Currently, the number of animal studies using ARNI is limited
(Table 1). In 2008, Pu et al. compared the ARB valsartan with
the ARNI combination valsartan +CGS25354 and a dual
ACE inhibitor/NEP inhibitor in stroke-prone spontaneously
hypertensive rats [22]. Compared with valsartan, both ARNI
and the dual ACE/NEP inhibitor were more effective in low-
ering blood pressure and decreasing vascular remodeling and
macrophage infiltration. The ACE/NEP inhibitor reduced car-
diac hypertrophy more than ARNI, possibly because the
ACE/NEP inhibitor also had a greater effect on blood pressure
compared with ARNI [22]. Because the study did not include
an ACE inhibition-only group, it is unclear if this was due to a
difference in effectiveness between ARB and ACE inhibition
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or if dual ACE/NEP inhibition had a stronger synergistic ef-
fect compared with ARNI.
In 2010, the first animal study using the ARNI LCZ696
was published. Gu et al. reported on the pharmacokinetics of
LCZ696 in beagle dogs and its pharmacodynamics in rats
[18]. Single oral administration of LCZ696 to rats transgenic
for human renin and angiotensinogen caused a dose-
dependent decrease in mean arterial pressure (MAP) com-
pared to baseline, while it increased plasma ANP concentra-
tion and immunoreactivity in Sprague-Dawley (SD) rats
chronically infused with exogenous A-type (atrial) natriuretic
peptide (ANP) [18]. LCZ696 was not compared with
valsartan alone.
Von Lueder et al. compared LCZ696with vehicle treatment
in SD rats after experimental myocardial infarction [23]. As
expected, after 4 weeks of treatment, LCZ696-treated rats had
a lower blood pressure, a higher cardiac output, a lower heart
weight and less cardiac fibrosis compared with vehicle treat-
ment. In vitro, Von Lueder et al. assessed the effects of
valsartan, AHU377, LBQ657 or valsartan+LBQ657 on rat
neonatal cardiac myocytes and fibroblasts, after Ang II pre-
treatment. Valsartan and LBQ657 both inhibited Ang II-
induced cardiac myocyte hypertrophy when applied separate-
ly. When applied simultaneously, valsartan+LBQ657 only
outperformed valsartan when a very low dose or a very high
dose of valsartan was combined with LBQ657 (fixed dose).
Valsartan decreased collagen accumulation in cardiac fibro-
blasts, while LBQ657 did not affect collagen accumulation.
Dual treatment with valsartan + LBQ657 consistently
inhibited Ang II-induced collagen accumulation more than
valsartan alone [23]. Unfortunately, in this study, LCZ696
treatment was not compared with valsartan in vivo.
Bai et al. pretreated mice with LCZ696, valsartan or vehi-
cle before inducing ischaemic brain damage by middle
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VasoconstrictorsVasodilatorsFig. 1 Opposing effects of
neprilysin (NEP) inhibition. NEP
degrades vasodilators (e.g. A-type
(atrial) natriuretic peptide (ANP)
produced by atrial myocytes, B-
type (brain) natriuretic peptide
(BNP) produced by ventricular
myocytes and urodilatin produced
by the distal convoluted tubule
and the collecting duct) as well as
vasoconstrictors (e.g. angiotensin
II (Ang II) and endothelin-1
produced by endothelial cells)
into inactive metabolites. The
effect of NEP inhibition with
LCZ696 may be unpredictable as
it depends on the relative
dominance of either vasodilators
or vasoconstrictors
Curr Hypertens Rep (2016) 18: 86 Page 3 of 10 86
cerebral artery occlusion [24]. Despite the absence of a blood
pressure difference between the three groups, LCZ696-treated
mice had a smaller ischaemic area compared with valsartan-
treated mice. LCZ696 caused a significant rise in serum ANP
levels, compared with valsartan. Both valsartan and LCZ696
induced an increase in serum renin activity and serum Ang II
concentration [24]. However, when calculating the dose of
LCZ696, the authors used equal weight ratios instead of equal
molar ratios and did not take in account area under the curve
data to provide similar exposure to valsartan [18, 25]. The
authors did not comment on the absence of a difference in
blood pressure between the three treatment groups.
Suematsu et al. used tenfold higher dosages of valsartan
and LCZ696, compared with Bai et al., in streptozotocin-
treated diabetic mice, after myocardial reperfusion injury
[26]. At the end of the 4-week treatment period, only
valsartan-treated animals had a significantly lower blood pres-
sure than vehicle-treated animals. Both valsartan- and LCZ696-
treated animals had a lower heart weight/body ratio than
vehicle-treated animals. LCZ696-treated animals displayed a
better ejection fraction, less cardiac fibrosis and lower cardiac
TGF-β and ANP expression compared with vehicle-treated
animals. How exactly LCZ696 exerted its beneficial effects
on TGF-β, fibrosis and cardiac function, independently from
blood pressure, remained unclear [26].
In a recent study by our group, ARB (irbesartan) and
ARNI (irbesartan +NEP inhibitor thiorphan) were com-
pared in diabetic, hypertensive rats. ARB and ARNI in-
duced a similar blood pressure-lowering effect, but ARNI-
treated animals displayed a lower heart weight, less pro-
teinuria and less focal segmental glomerulosclerosis as
compared to ARB-treated animals [27]. When analysing
the eyes of these diabetic animals, ARNI-treated animals
also had less severe diabetic retinopathy [Qiuhong Li,
University of Florida, Gainesville, USA, unpublished
observations].
This led to the conclusion that ARNI exerts beneficial ef-
fects in the heart, kidney and eye independent of its blood
pressure-lowering effect. Effects could not easily be explained
on the basis of changes in RAAS activity, natriuretic peptides
or cGMP. Future studies should address to what degree ARNI
affects local concentrations of natriuretic peptides, e.g. in the
kidney. Here, natriuretic peptides might improve renal
haemodynamics, but also exert anti-inflammatory effects.
In an earlier study in nondiabetic hypertensive rats, we
observed that the dose of the NEP inhibitor given on top of
an ARB is highly critical [28•]: when the NEP inhibitor was
dosed too high, circulating endothelin-1 levels started to rise,
and this resulted in an increase in renal sodium-hydrogen ex-
changer type 3 protein expression and an upregulation of con-
strictor vascular endothelin type B receptors. As a conse-
quence, blood pressure rose and a beneficial effect on cardiac
hypertrophy was no longer observed. Since NEP is capable of
cleaving endothelin-1, these findings are not unexpected and
emphasize the need to measure changes in endothelin-1 in
future ARNI studies.
Human Studies
Effects in the General Hypertensive Population
ARNI was compared to valsartan in a proof of concept trial, to
study whether neprilysin inhibition on top of ARB indeed
enhances blood pressure reduction (Table 2) [25]. The study
included 1328 patients with mild to moderate uncomplicated
Table 1 Comparison of LCZ696
to other anti-hypertensive
therapies or vehicle in animal
models
Year Author Animal model ARNI (ARB+NEPi) Comparison
ARB Other
2008 Pu et al. SHRSP rats Valsartan +CGS25354 Valsartan CGS30440b
2010 Gu et al. Beagle dogs and SD rats Valsartan + sacubitrila – –
2015 Von Lueder
et al.
SD rats Valsartan + sacubitrila – Vehicle
2015 Bai et al. C57BL/6J mice Valsartan + sacubitrila Valsartan Vehicle
2015 Roksnoer
et al.
TGR (mRen2) rats Irbesartan + thiorphan Irbesartan Thiorphan,
vehicle
2016 Suematsu
et al.
C57BL/6J mice + STZ
diabetes
Valsartan + sacubitrila Valsartan Vehicle
2016 Roksnoer
et al.
TGR (mRen2) rat + STZ
diabetes
Irbesartan + thiorphan Irbesartan Vehicle
ACEi angiotensin-converting enzyme inhibitor, NEPi neprilysin inhibitor, SHRSP stroke-prone spontaneously
hypertensive rats, SD Sprague Dawley, STZ streptozotocin
a LCZ696
bDual ACEi/NEPi
86 Page 4 of 10 Curr Hypertens Rep (2016) 18: 86
hypertension. At baseline, untreated mean sitting systolic
blood pressure (SBP) averaged 155.7 mmHg and mean sitting
diastolic blood pressure (DBP) averaged 99.7 mmHg. Patients
with diabetes, cardiac or renal disease were excluded.
Treatment with 100, 200 or 400 mg LCZ696 once daily was
compared to respectively 80, 160 or 320 mg valsartan once
daily (i.e. equipotent amounts of valsartan [18]), or placebo,
for a treatment period of 8 weeks. Most of the treatment effect
occurred in the first week after start of the study drug, and the
effect was almost maximal at 4 weeks of treatment. Treatment
with 200 mg LCZ696 lowered mean sitting SBP with
11.0 mmHg and mean sitting DBP with 6.1 mmHg.
This is an additional reduction of –5.28 mmHg (95%
CI –8.28 to –2.28) in SBP and –2.97 mmHg (95% CI
–4.88 to –1.07) in DBP when compared to 160 mg
valsartan. LCZ696-treated patients responded 14% more
often to treatment, attested by either a blood pressure
below 140/90 mmHg or more than 20 or 10 mmHg
reduction in SBP or DBP, respectively. Additional am-
bulatory blood pressure measurements demonstrated that
these reductions were maintained throughout the day,
although responses were most pronounced during night-
time. These outcomes did not improve further with
400 mg LCZ696 versus 320 mg valsartan. Occurrence
rate or severity of reported adverse events did not differ
between LCZ696 and valsartan.
Effects in Heart Failure Populations
RAS blockade reduces cardiovascular and all-cause mortality
as well as hospitalization for worsening heart failure in pa-
tients with reduced ejection fraction (HFrEF) [29]. ACEi has
obtained a central position herein, since enalapril was shown
to greatly improve outcome already 25 years ago [30, 31]. A
Table 2 Main characteristics of LCZ696-treated patients and effects of LCZ696 treatment
Study Ruilope et al. McMurray et al. Solomon et al. Ito et al.
(PARADIGM-HF) (PARAMOUNT)
LCZ696-treated patients (n) 168 4187 149 32
Main inclusion criterium Hypertension HFrEF HFpEF CKD
Additional specifications LVEF 29.6% (6.1) LVEF 58% (7.3) Stage 3 or 4
Age (years) 53 (10.2) 63.8 (11.4) 71 (9.4) 66 (9.1)
Sex (% male) 57 78 43 75
Race (% black) 8 5 NP 0
Dosage LCZ696 (mg) 200 200 200 200–400
(titration)
Dosing frequency (per day) 1 2 2 1
Duration of treatment (weeks) 8 116 36 8
Concomitant anti-hypertensive medication
β-blockers (%) 0 93 79 0
Diuretics (%) 0 80 100 6
Mineralocorticoid receptor
antagonists (%)
0 54 19 0
Calcium channel blockers (%) 0 NP NP 38
Baseline blood pressure
Systolic (mmHg) 156.8 (12.0) 122 (15) 136
(IQR 130 to 145) 151.6 (10.3)
Diastolic (mmHg) 99.9 (4.1) NP 79
(IQR 74 to 85) 86.9 (10.8)
Change compared to baseline blood pressure
Systolic (mmHg) −11.0 (NP)** NP −7.5 (15.0)* −20.5 (11.3)$
Diastolic (mmHg) −6.1 (NP)* NP −5.1 (10.8)* −8.3 (6.3)$
Main outcome Blood pressure
reduction*
CVD-mortality/HF-hospitalization
reduction#
Left atrial volume
reduction*
Blood pressure$
UACR
reduction
Data are represented as mean (SD), unless otherwise indicated. Statistical significance was calculated using a Student’s t test (*P< 0.01, **P< 0.001
compared with valsartan-treated controls; #P< 0.001 compared with enalapril treated controls; $P< 0.001 compared to baseline)
NP not provided
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recent meta-analysis of three trials that studied the combina-
tion of RAS and neprilysin inhibition in HFrEF patients dem-
onstrated a 15% risk reduction for the composite endpoint of
death or hospitalization when compared to ACEi alone [32].
Unfortunately, combination of ACEi and neprilysin inhibition
(omapatrilat) is more likely to cause serious angioedema [33,
34], prompting discontinuation of drug development.
Therefore, the effect of ARNI on HFrEF outcome was studied
in the Prospective Comparison of ARNI With ACEi to
Determine Impact on Global Mortality and Morbidity in
Heart Failure (PARADIGM-HF) trial (Table 2) [35•]. This
study included 8399 patients with a mean left ventricular ejec-
tion fraction (LVEF) of 29.5%. Nearly all patients continued
receiving other drugs known to improve survival. Patients
were randomly assigned to receive 200 mg LCZ696 twice
daily or 10 mg enalapril twice daily. The trial was stopped
early with a mean follow-up duration of 27 months due to a
benefit in favour of LCZ696. The risk for the composite pri-
mary endpoint of cardiovascular-related death or first hospi-
talization for worsening heart failure was reduced by 20% in
LCZ696-treated patients. In addition, all-cause mortality was
reduced by 16%. Patients with lower LVEF had a 9% in-
creased risk per five-point reduction of ejection fraction but
benefitted equally from treatment when compared to patients
with higher LVEF [36]. The beneficial effect on mortality is
mainly due to a reduction in sudden death or death from pro-
gression of heart failure [37]. Progressive impairment of func-
tional capacity due to nonfatal worsening of symptoms was
assessed by the Kansas City Cardiomyopathy Questionnaire
(KCCQ). This score improved in patients treated with
LCZ696 and declined in patients treated with enalapril (mean
difference between groups was 0.95 points on a scale of 1 to
100). However, patients were 34% less likely to visit the emer-
gency room and fewer patients required intravenous drug ther-
apy, rehospitalization or admission to an intensive care unit.
Moreover, LCZ696-treated patients were 22% less likely to
require surgical implantation of a left ventricular assist device
(LVAD) or heart transplantation [38]. Concomitant hyperten-
sion was present in 71% of the study population. Mean SBP at
baseline averaged 122 ± 15 mmHg. LCZ696 treatment
lowered SBP with an additional 3.2±0.4 mmHg when com-
pared to enalapril. Consequently, LCZ696-treated patients
were more likely to develop symptomatic hypotension (14
versus 9.2%). In addition, more cases of angioedema were
reported (19 versus 10 patients), although this difference was
not significant. Conversely, patients treated with enalapril
were more likely to develop hyperkalaemia or cough.
Currently, the European Society of Cardiology (ESC) recom-
mends the use of sacubitril/valsartan instead of ACEi in am-
bulatory patients who remain symptomatic despite optimal
therapy [39].
Almost 50% of heart failure patients have a preserved ejec-
tion fraction (HFpEF). RAS inhibition is less beneficial in this
group of patients. Although it reduces the risk of hospitaliza-
tion due to worsening of symptoms with 12%, there are no
improvements in cardiovascular or all-cause mortality [29].
Efficacy and safety of LCZ696 treatment in HFpEF patients
was studied in Prospective Comparison of ARNI with ARB
on Management of Heart Failure with Preserved Ejection
Fraction (PARAMOUNT) (Table 2) [40]. In this study, 301
patients with a mean LVEF of 58% were included. At base-
line, most patients were treated for hypertension (93.5%) and
mean blood pressure averaged 136/79 mmHg. Patients were
randomly assigned to 200 mg LCZ696 twice daily or 160 mg
valsartan twice daily for a treatment period of 36 weeks. A
significantly greater degree of blood pressure reduction was
observed in LCZ696-treated patients than in valsartan-treated
patients (−7.5 (±15) versus −1.5 (±16) mmHg for mean sitting
SBP; −5.1 (±10.8) versus −0.34 (±11.5) mmHg for mean sit-
ting DBP). Ventricular wall stretch induces production of pro-
B-type natriuretic peptide (proBNP). N-terminal pro-B-type
natriuretic peptide (NT-proBNP) is the inactive side product
yielded upon cleavage of proBNP into biologically active
BNP. Elevated serum NT-proBNP is a well-known marker
for heart failure severity, as it is associated with increased risk
of mortality and hospitalization [41]. NT-proBNP is not de-
graded by NEP and as such has a longer half-life than BNP. A
decrease in NT-proBNP levels suggests reduced proBNP pro-
duction due to reduced cardiac wall tension (Fig. 2), while an
increase in BNP either suggests the opposite or might be due
to NEP inhibition. In HFrEF patients, LCZ696 reduced NT-
Ventricular wall stretch
proBNP
proBNPBNP
NEP
Inacve metabolites
LCZ696
High blood pressure
AT1R
-NT
Fig. 2 Effect of LCZ696 on BNP and NT-proBNP production. LCZ696
lowers blood pressure by simultaneous blockade of angiotensin II type 1
receptors (AT1R) and inhibition of neprilysin (NEP). Relative dominance
of either effect determines BNP levels. NT-proBNP represents effects on
ventricular wall stretch, as it is not degraded by neprilysin
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proBNP and increased BNP [38]. In HFpEF patients, LCZ696
also reduced NT-proBNP at 12 weeks of treatment [40]. At
36 weeks, this difference was no longer significant. However,
at this time point, left atrial width (mean difference 0.7 mm)
and volume (mean difference 4.97 mL) were reduced in fa-
vour of LCZ696. These effects were independent of blood
pressure lowering [42]. Effect of ARNI treatment on mortality
and hospitalization in HFpEF patients is currently being stud-
ied in Prospective Comparison of ARNI with ARB Global
Outcomes in Heart Failure with Preserved Ejection Fraction
(PARAGON-HF).
Effects in Other High-Risk Populations
CKD patients are at high risk for cardiovascular morbidity and
mortality, added on top of the risk of progression towards
ESRD. Diabetes and hypertension are the most common
causes of CKD worldwide and additionally independent risk
factors for cardiovascular complications. Simultaneous pres-
ence of all three risk factors is not uncommon. However, the
complex interplay between these diseases does appear to alter
treatment responses. For HFrEF patients with renal function
decline, regardless of cause and comorbidities, benefit of treat-
ment with LCZ696 was equal for patients with eGFR ≥60mL/
min/1.73 m2 and reduced eGFR (between 30 and 60 mL/min/
1.73 m2) [36]. However, treatment of diabetic HFrEF patients
with 200 mg LCZ696 twice daily did not reduce cardiovascu-
lar and all-cause mortality when compared to valsartan, al-
though risk for heart failure hospitalization was improved,
comparable to that of nondiabetic patients [43]. Interestingly,
LCZ696 reduced NT-proBNP levels particularly in HFpEF
patients with diabetes, indicating a more pronounced reduc-
tion of ventricular wall tension when compared to nondiabetic
patients [40]. Furthermore, LCZ696 may prevent progression
of renal damage especially in patients with diabetic nephrop-
athy. LCZ696 reduced urinary albumin-to-creatinine ratio
(UACR) by 15.1% in patients with hypertension andmoderate
to severe renal impairment, with a greater effect in patients
with macroalbuminuria than in micro- or normoalbuminuria
[44•]. Conversely, a small but significant increase in UACR
(2.4 to 2.9 mg/mmol) was observed in LCZ696-treated
HFpEF patients [45], despite the fact that eGFR was better
preserved after 36 weeks of treatment (−1.6 versus −5.2 mL/
min/1.73 m2) [41]. Increased albuminuria in these patients
might be caused by ANP-induced relaxation or anti-
proliferative effects in renal mesangial cells [46, 47], in com-
bination with impaired proximal tubular protein reabsorption
[48]. No significant differences in renal outcome were found
between patients with HFrEF treated with either LCZ696 or
enalapril, although numerically fewer patients developed
ESRD with LCZ696 (8 versus 16 patients, P=0.11). These
favourable outcomes might be explained by a reduction of
renal tubulointerstitial fibrosis and focal segmental
glomerulosclerosis, as observed in ARNI-treated diabetic, hy-
pertensive rats when compared to ARB-treated controls [27].
Moreover, LBQ657 reduced the Ang II-stimulated increase in
collagen synthesis in renal mesangial cells [49]. These effects
occurred in a blood pressure-independent manner.
Despite these potential advantages in renal outcome,
there may be some limitations to the use of LCZ696 in
CKD patients. Sacubitrilat is primarily eliminated by
the kidneys. The degree of decline in eGFR correlated
with increased maximum plasma drug concentration
and half-life, as the percentage of sacubitrilat excreted
in urine decreased progressively. Therefore, normoten-
sive patients with moderate to severe renal impairment
more often developed orthostatic hypotension [20]. In
PARADIGM-HF, blood pressure was well-controlled
due to the continued use of several classes of anti-
hypertensive drugs, and mean SBP at baseline aver-
aged 122 ± 15 mmHg (Table 2) [35•]. Consequently,
hypotension occurred more often in patients that were
subsequently exposed to LCZ696 and was the most
common reason for dose reduction, whereas a higher
serum creatinine level was the main predictor of this
phenomenon. This indicates that indeed normotensive
patients with reduced renal function are at higher risk
of developing hypotension. However, hypertension is
both a cause and consequence of CKD and blood pres-
sure is often poorly controlled in these patients [50].
Therefore, the safety and efficacy of LCZ696 was
assessed in 32 Japanese patients with hypertension
and CKD stage 3 (78.1%) or stage 4 (21.9%)
(Table 2) [44•] . Init ial treatment with 100 mg
LCZ696 once daily reduced mean sitting blood pres-
sure to 130/80 mmHg or lower in 19% of the popula-
tion. The dosage in other patients was increased to
either 200 mg (25%) or 400 mg (56%) LCZ696 once
daily, for a total treatment duration of 8 weeks. The
blood pressure-lowering effect occurred mostly in the
first week of treatment and was maximal at 4 weeks.
Stage 3 CKD patients had a mean blood pressure of
152.1/87.7 mmHg at baseline. With LCZ696, 60% of
the patients had an adequate SBP reduction of
≥20 mmHg or values ≤130 mmHg and in 76% of the
patients an adequate DBP reduction of ≥10 mmHg or
values ≤80 mmHg. Mean reduction in all patients was
21.3/9.1 mmHg. LCZ696 treatment was also effective
in stage 4 CKD patients. Their mean baseline blood
pressure of 149.8/83.9 mmHg was reduced by 17.7/
5.5 mmHg. Adequate SBP and DBP responses were
obtained in 57% of the patients. No events of hypo-
tension were reported in either CKD class, although
plasma doses of LBQ657 tended to increase with de-
creasing renal function. The safety of LCZ696 treat-
ment in CKD patients and effects on renal function
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are currently being studied in the United Kingdom
Heart and Renal Protection III (HARP-III) trial [51].
Limitations
NEP is involved in the degradation of many peptides,
among which amyloid beta 1-42 (Aβ1-42). Intracerebral
infusion of the NEP inhibitor thiorphan induces hippo-
campal accumulation and deposition of Aβ1-42 in rats,
already at in vivo concentrations of 2.5 ng/mL [52].
Aggregation of Aβ1-42 is believed to play a critical role
in the development of Alzheimer’s disease (reviewed in
[53]). Blood-brain barrier penetration of LBQ657 was
assessed in 17 healthy volunteers treated with 400 mg
LCZ696 once daily [54]. After 2 weeks of treatment, a
mean maximum drug concentration of 19.2 (±11.3) ng/
mL was found in cerebrospinal fluid (CSF). There was
no effect on CSF Aβ1-42 concentration when LCZ696-
treated individuals were compared to placebo-treated
controls. Differences in plasma Aβ1-42 concentration
were not determined, although plasma Aβ1-40 concentra-
tion increased by 50%. These results do not dispel all
concerns. CSF clearance of Aβ appears to be a minor
route, as the blood-brain barrier traffics most of the
brain Aβ directly out into the peripheral circulation
[55]. Additionally, the measurements in placebo-treated
controls demonstrate high variability of CSF Aβ1-42
concentration. Therefore, these results do not rule out
the possibility of accumulation Aβ1-42 in the brain,
which would go undetected by CSF measurements.
Additionally, hypertension and diabetes are known to
contribute to blood-brain barrier dysfunction, rendering
these patients more vulnerable, as NEP inhibition might
induce Aβ1-42 in a dose-dependent manner [56].
However, these risks might be more relevant for dis-
eases with greater longevity than HFrEF.
Conclusions
In summary, when compared to ARB, ARNI superiorly reduces
blood pressure in uncomplicated, essential hypertension as well as
in heart failure and CKD populations. When compared to ACEi,
ARNI superiorly prevents death and hospitalization in HFrEF pa-
tients that already receive all other medication known to improve
outcome. ARNI appears to improve renal outcome, particularly in
high-risk, multi-morbid populations. Although patients with con-
comitant heart failure and diabetes show no reduction in mortality,
they do demonstrate reverse left atrial remodeling, less heart failure
hospitalization and reduced albuminuria. Preclinical data in hyper-
tensive, diabetic rats additionally suggests blood pressure-
independent improvement of renal damage, attested by decreased
proteinuria and abated glomerulosclerosis. ARNI might mediate
these effects by impeding activation of the proinflammatory cyto-
kine TGF-β, which plays a central role in the fibrotic response and
accumulation of collagen. This could explain the improved renal
outcomes but requires further experimental study. Importantly,
ARB and ARNI have not yet been compared in patients with
CKD due to diabetes and hypertension, and thus the results of
the HARP-III trial are anxiously awaited [51]. Until that moment,
the application of ARNI as a renoprotective drug for this high-risk
patient population is hampered. Moreover, sacubitrilat, the active
neprilysin-inhibiting component, is eliminated by the kidney.
Sacubitrilat-exposed normotensive patients with impaired renal
function can therefore, due to increased exposure, develop hypo-
tension. This is less likely to be a problem for the hypertensive
population. Caution is advised regarding the risk of cerebral Aβ1-
42 accumulation and Alzheimer’s disease in populations with a
longer median survival. Finally, we need additional insight into
the mechanism of action of ARNI. Although a decrease in NT-
proBNP and a rise in BNP have been reported [38], this might be
an assay artefact. Indeed, ARNI may promote peptide glycosyla-
tion, thereby affecting not only proBNP cleavage but also the
assays of NT-proBNP and BNP: NT-proBNP would become in-
visible, while proBNP would additionally be detected in BNP
assays [57•]. Another complicating factor is that BNP of all natri-
uretic peptides is the least susceptible to degradation by NEP and
as such acts as an endogenous inhibitor of NEP [58]. If so, patients
with elevated BNP levels already undergo NEP inhibition and
might respond less or not at all to LCZ696.
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